Trial Will Evaluate Use of Pembrolizumab, Known as Keytruda®*, With Cesium-131 and Surgical Resection RICHLAND, Wash., June 17, 2020 (GLOBE NEWSWIRE) — Isoray, Inc. (NYSE American: ISR) today announced that it has entered into a research grant agreement with the...
RICHLAND, WASHINGTON – June 2, 2020 – Isoray, Inc. (NYSE American: ISR) today announced that the results of a new ten year study show positive outcomes for low-risk and intermediate-risk prostate cancer patients treated with Isoray’s Cesium-131 (Cesium Blu) internal...
RICHLAND, WASHINGTON – May 12, 2020 – Isoray, Inc. (NYSE American: ISR) today announced that the Centers for Medicare and Medicaid Services (CMS) has approved 64 ICD-10-PCS billing codes used for reimbursement of Cesium-131 (Cesium Blu™) for the hospital in-patient...
Record Revenue and Gross Profit Revenue Increased 50% Year-Over-Year RICHLAND, WASHINGTON – May 12, 2020 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body,...
Conference Call is May 12 at 4:30 p.m. ET/1:30 p.m. PT RICHLAND, WASHINGTON – May 4, 2020 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in brachytherapy powering expanding treatment options throughout the body, today announced that it...
Gains in engagement, conformal coverage, seamless logistics, planning, and procedural efficiency drive Wisconsin brachytherapy program’s transition to Cesium Blu™. “If it ain’t broke, don’t fix it.” The ageless axiom holds true in so many circumstances that it will...
“The potential to smooth out our workflow and increase our potential candidate pool for the procedure given the ability to do brachytherapy with Cesium Blu prior to EBRT is a compelling motivation for adding it to our prostate cancer treatment arsenal,”- Dr. Bobby...
Welcome to the Isoray’s Prostate Cancer Connect Podcast! Each episode of the series, Dr. John Sylvester and featured guests will be talking in-depth about the current status and advancements in brachytherapy for prostate cancer treatment. How do we find the right...
Revenue Increased 16% Year-Over-Year Gross Profit Increased 45% Year-Over-Year RICHLAND, WASHINGTON – February 11, 2020 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options...
Bundled Treatment Program Provides New Opportunities For Treating Physicians and Patients Facing Limited Options RICHLAND, WASHINGTON – February 5, 2020 – Isoray, Inc. (NYSE American: ISR) today announced an executed agreement with MIM Software to deliver a novel...
